J Korean Cancer Assoc.  2000 Oct;32(5):863-874.

Alterations of HLA Class I and II Antigen Expressions in Preinvasive, Invasive and Metastatic Cervical Cancers

Affiliations
  • 1Department of Obstetrics and Gynecology and Molecular Genetic Laboratory, College of Medicine, The Catholic University of Korea, Seoul, Korea. jinwoo@cmc.cuk.ac.kr

Abstract

PURPOSE: The relationship between altered HLA expressions and cervical carcinogenesis is not fully elucidated.
MATERIALS AND METHODS
The histological evaluation comprised of 21 microinvasive squamous cell carcinoma (SCC), 26 invasive SCC, 3 microinvasive adenocarcinoma and 9 invasive adeno carcinoma of cervix. We used monoclonal antibodys (mAbs) to HLA class I beta2-microglobulin (L368), HLA class I B/C heavy chains (HC-10) and HLA class II heavy chain (LG II-612.14).
RESULTS
In tissues from microinvasive SCC, the expressions of B/C heavy chains and class II heavy chain were significantly decreased. The expressions of beta2-microglobulin, B/C chains, and class II heavy chain in SCC were all significantly decreased. Especially, in the metastatic tissue from the same patient, the expressions of beta2-microglobulin and B/C chains showed to be somewhat decreased compared to those in primary tumor tissues, and the expression of class II heavy chain was decreased further than that in primary lesion. In primary invasive adenocarcinoma, the expression of B/C chains was significantly decreased.
CONCLUSION
These results suggest that alterations of HLA class I and II expressions seem to occur at a particular step in tumor development and depend on tissue types: when the tumor becomes invasive and starts to metastasize.

Keyword

Cervical neoplasm; HLA class I; HLA class II

MeSH Terms

Adenocarcinoma
Carcinogenesis
Carcinoma, Squamous Cell
Cervix Uteri
Female
Humans
Uterine Cervical Neoplasms
Full Text Links
  • JKCA
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr